According to Fact, the global market for cancer immunotherapy is expected to generate US$ 119.4 billion by 2021. MR is a market research and information company. By the end of the 2021-2031 evaluation period, the market is expected to exceed US$310 billion, representing a staggering CAGR of 10%. The cancer immunotherapy market is driven by consumer preference for immunotherapies and the increasing number of people diagnosed with cancer. In addition, many important companies are focused on mergers and acquisitions and potential acquisitions.
Download a sample copy of this report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4367
By the end of 2020, demand for cancer immunotherapy will have increased at a startling 14% value CAGR. By spending money on research and development, businesses are concentrating on expanding their potential.
According to the International Organization for Research on Cancer, there will be an estimated 19.3 million new cases of cancer in 2020, excluding 18.1 million cases of non-melanoma skin cancer, and about 10 million fatalities, including 9.9 million cases of non-melanoma mortality. With an expected 11.7% increase in new cases, female breast cancer has surpassed lung cancer as the most prevalent kind of diagnosis.
Key Companies Profiled
- Amgen Inc.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- F. Hoffmann-La Roche Ltd.
- Janssen Biotech, Inc.
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Spectrum Pharmaceuticals, Inc.
- Sanofi
- Takeda Pharmaceuticals
Impact of COVID-19 on Cancer Immunotherapy Market:
The COVID-19 pandemic and its impact on the Immuno-Oncology market, as well as future forecasts for the market are covered in the study. It provides a breakdown of how the epidemic has impacted the global market. The chain of demand and supply was immediately interrupted by the outbreak. The economic impact on businesses and financial markets is also assessed in the study on the Cancer Immunotherapy Market. To provide clients with the information and methods to address their business challenges during and after the COVID-19 pandemic, Futuristic Reports gathered advice from many industry representatives and conducted secondary and primary research. engaged.
Key Segments Covered
- By Therapy
- Monoclonal Antibody
- Immune Checkpoint Inhibitors
- PD-1/PD-L1
- CTLA-4
- Immune System Modulators
- Cancer Immunotherapy Vaccines
- Other
- By Cancer Type
- Lung
- Colorectal
- Breast
- Prostate
- Melanoma
- Blood
- Other
- By End User
- Hospitals
- Ambulatory Surgical Centres
- Cancer Research Centres
- Clinics
- By Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
A simple approach to research
To extrapolate the data for this report, the analysis uses modeling-based techniques and triangulation. After fully understanding the market and evaluating the application, type, form and end use of the product segment under study, a demand side approach is used to estimate the sales of the target product segment. This is followed by a supply-side valuation of the value produced during the specified period. Statistics and data are collected at the regional level, pooled and integrated at the global level to determine the size of the global market.
This extensive study was developed using validated and well-established approaches. The weighted chapters of the study provide information and analysis on important market segments.
The key business strategies discussed in this market study are
1) In the aftermath of globalization in the Immuno-Oncology market, how are market players maintaining their significant competitive edge?
2) How will changing market dynamics of the Immuno-Oncology sector impact the company outlook going forward?
3) What are the prominent commercial strategies influencing the competition in the Immuno-Oncology market?